The combined space of 1,400 square meters across the two sites will specifically focus on medical imaging services, including an advanced image analysis center for BioClinica’s network of European radiologists and imaging specialists.
As far as why this additional space may be necessary, John Hubbard, CEO of BioClinica, told Outsourcing-Pharma.com: “Imaging endpoints and biomarkers are becoming increasingly important as primary and secondary endpoints for demonstrating efficacy and safety in clinical trials. This is reflected in the current growth of the medical imaging sector at approximately 7-10% annually.”
Medical imaging can also provide early insight for the diagnosis, prognosis, and progression of complex diseases, which can help sponsors make decisions on trial enrollment and the advancement of pipeline candidates, Hubbard said, noting this is “especially true in the rapidly growing therapeutic areas of oncology, inflammatory disease, musculoskeletal disease, and neurological disorders.”
In addition to the imaging services, BioClinica’s eClinical Solutions business will also operate from these two new offices, Hubbard said. “We are seeing a high level of interest in our clinical technology products, including OnPoint CTMS (clinical trial management system) and Compass (intelligent risk based monitoring), designed to help sponsors run faster, more efficient clinical trials.”
David Herron, BioClinica’s President of Medical Imaging, Cardiovascular Safety, and Molecular Markers, added: “Our expansion will provide the resources needed for regional scientific and medical experts to assemble and deliver high quality central review of imaging data for multisite trials in Europe.”